Cartesian Therapeutics (RNAC) Net Income towards Common Stockholders (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Net Income towards Common Stockholders of -$26.6 million for Q1 2026, down 31.95% year-over-year from -$39.2 million in Q1 2025, and up 66.06% quarter-over-quarter from -$78.5 million in Q4 2025.
Cartesian Therapeutics (RNAC) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Net Income towards Common Stockholders for 12 consecutive years, with -$26.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 31.95% year-over-year to -$26.6 million; the TTM figure through Mar 2026 stood at -$116.5 million (down 76.35% YoY), while the FY2025 annual figure was -$130.3 million, down 68.26% from the prior year.
- Net Income towards Common Stockholders rose to -$26.6 million in Q1 2026 per RNAC's latest filing, from -$78.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $13.4 million in Q2 2022 and bottomed at -$196.7 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged -$24.8 million across 5 years, with a median of -$19.2 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 5275.19% — and 2023, when it tumbled 3437.15%.
- Cartesian Therapeutics' Net Income towards Common Stockholders stood at $5.9 million in 2022, then sank by 3437.15% to -$196.7 million in 2023, then surged by 87.14% to -$25.3 million in 2024, then plunged by 210.45% to -$78.5 million in 2025, then jumped by 66.06% to -$26.6 million in 2026.
- Business Quant data shows RNAC's Net Income towards Common Stockholders at -$26.6 million in Q1 2026, -$78.5 million in Q4 2025, and -$24.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 13.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.72 Mn |
| Mar 31, 2026 | -26.64 Mn |
| Dec 31, 2025 | -78.51 Mn |
| Sep 30, 2025 | -24.61 Mn |
| Jun 30, 2025 | 13.26 Mn |
| Mar 31, 2025 | -20.19 Mn |
| Dec 31, 2024 | -25.29 Mn |
| Sep 30, 2024 | -30.21 Mn |
| Jun 30, 2024 | 9.63 Mn |
| Mar 31, 2024 | -24.88 Mn |
| Dec 31, 2023 | -196.66 Mn |
| Sep 30, 2023 | -9.00 Mn |
| Jun 30, 2023 | -11.39 Mn |
| Mar 31, 2023 | -19.18 Mn |
| Dec 31, 2022 | 5.89 Mn |
| Sep 30, 2022 | -7.89 Mn |
| Jun 30, 2022 | 13.35 Mn |
| Mar 31, 2022 | 10.08 Mn |
| Dec 31, 2021 | 12.24 Mn |
| Sep 30, 2021 | -17.89 Mn |